NEW YORK, May 15, 2026, 03:53 EDT
Friday’s U.S. session brings a narrow focus: AI, China headlines, and fresh drug data—all with direct hits from Cisco, Nvidia, just-listed Cerebras, Boeing, Ford, and Biogen. On Thursday, tech momentum drove the S&P 500 and Nasdaq to new records, while the Dow finished up at 50,063.46.
The timing is crucial: markets are moving as much on policy expectations as on earnings now. On Polymarket, odds for a U.S.-China tariff deal by May 31 are set at 57%. A different market sees a 72% probability that the Federal Reserve won’t cut rates in 2026. So, traders are factoring in some hope for trade easing, but bets on lower rates are thin.
So today’s lineup isn’t just about stocks jumping around. Cisco’s showing if AI dollars are reaching past the chip makers. Nvidia’s in the spotlight as China policy shifts from talk to real shipments. Boeing’s outcome hangs on summit negotiations. Ford’s trying to prove buyers want its storage tech. And Biogen—investors are weighing just how much disappointment they can stomach after that mixed trial.
Cisco leads off. Nearly 4,000 jobs are on the chopping block as the company pivots investments into AI and other growth bets, though it bumped its annual revenue target higher after racking up $5.3 billion in AI infrastructure orders from hyperscalers this fiscal year. CEO Chuck Robbins called for “focus, urgency” to stay ahead in AI. Direxion’s Ryan Lee noted the spending spree is turning into “more than just chips.” Reuters
Nvidia’s fortunes are still closely tied to U.S.-China politics. U.S. Trade Representative Jamieson Greer told reporters chip export controls barely came up during recent talks in Beijing. Reuters added that roughly 10 Chinese firms have received a green light from U.S. officials to buy Nvidia’s H200 AI processor—though none have gotten their hands on the chips yet. Until those shipments show up, Nvidia shares remain vulnerable to any new developments on China policy, even with the sector’s recent run.
Cerebras just delivered the year’s largest IPO, raising $5.55 billion. Shares debuted at $350, far above the $185 offer, putting the AI chipmaker’s fully diluted valuation at roughly $106.75 billion. CEO Andrew Feldman sees AI demand surging—his word: “explode.” But Nicholas Smith of Renaissance Capital flagged the valuation as “quite high even out to 2028.” Reuters
Boeing’s China headache is going in the other direction. Shares slipped after President Donald Trump put the number of jets China would buy at 200—well short of the 500-plane deal sources had floated was on the table. Airbus, meanwhile, has been making inroads in China over the last ten years. “Less than hoped for,” is how Matt Akers at BNP Paribas summed up the market mood after the pledge, with investors clearly disappointed. Reuters
Ford is pushing into a new AI-adjacent area: energy storage. The stock jumped as investors zeroed in on Ford Energy, the division building storage systems with lithium iron phosphate batteries—a cheaper chemistry, typically found in big stationary setups—for use by data centers, utilities, and industrial buyers. Morgan Stanley analysts described Ford’s licensing agreement with CATL as an “underappreciated strategic competitive advantage,” with initial deliveries slated for late 2027. Reuters
Biogen is in focus after announcing plans to push its Alzheimer’s candidate, diranersen, into late-stage trials. This move comes despite the drug failing to hit the main target in its mid-stage study—higher doses didn’t outperform the lower ones. Diranersen zeroes in on the tau protein, which has been tied to Alzheimer’s progression. Bernstein’s Christian Moore summed it up: “not a worst-case outcome,” he said, but still a “net-negative.” Reuters
Still, market breadth remains a concern. FTSE Russell figures show almost half of the FTSE All-World Index’s April gains were driven by just 13 AI-focused stocks. Adam Turnquist at LPL Financial pointed out that only 53% of S&P 500 constituents are trading above their 200-day moving averages—a weaker showing than typically seen at record highs. Should AI-linked shares falter, there’s not much support left elsewhere.
This Friday, attention lands on whether Cisco keeps its AI-order premium, if Nvidia can stay above the noise from China, and whether Cerebras dodges post-IPO jitters. Boeing’s in focus for any extra color on its China order. Ford needs to keep energy storage front and center for shareholders. And Biogen has a task: persuading drug buyers that missing an endpoint doesn’t end the story.
